TLR4 signaling induces functional nerve growth factor receptor p75NTR on mouse dendritic cells via p38MAPK and NF-kappa B pathways.
Many neuropeptides that are produced by immune cells have been shown to be involved in the pathogenesis of immunological disorders. Nerve growth factor (NGF) and its receptors are found to be widely expressed in the immune system and regulate both innate and adaptive immune responses. However, the underlying mechanisms by which NGF contributes to pathogenesis of inflammatory diseases remain to be fully understood. Dendritic cells (DCs) are potent initiator for inflammatory and immune responses upon recognization and activation of Toll-like receptors (TLRs). In this study, we demonstrated that stimulation with TLR ligand lipopolysaccharide (LPS), but not lipoteichoic acid (LTA), Poly (I:C) and CpG oligodeoxynucleotide (ODN), could significantly induce expression of NGF and NGF receptor p75(NTR) on mouse bone marrow-derived DCs (BMDCs) in vitro in dose- and time-dependent manners. The expression of NGF and NGF receptor p75(NTR) also increased on splenic DCs isolated from the mice injected with LPS in vivo. However, there was no such effect on DCs derived from TLR4-deficient mice, indicating the LPS-induced upregulation of NGF and p75(NTR) was TLR4 pathway-dependent. Furthermore, LPS-induced upregulation of NGF and p75(NTR) could be inhibited by p38MAPK inhibitor SB203580 and NF-kappaB inhibitor PDTC, suggesting TLR4-triggered activation of p38MAPK and NF-kappaB pathways are responsible for the process. Interestingly, NGF could markedly promote LPS-pretreated BMDCs to secret IL-12p40 and TNF-alpha, which could be abolished by pretreatment with p75(NTR) antagonist or the specific small interference RNA duplex targeting p75(NTR) (p75-siRNA), suggesting the inducible p75(NTR) is critical for the TLR4-initiated inflammatory effect of NGF on BMDCs. Thus, TLR4 signaling can induce expression of NGF and p75 (NTR) on DCs via activation of p38 MAPK and NF-kappaB pathways, suggesting that NGF may be involved in the pathogenesis of inflammatory diseases.
Jiang
Yingming
Y
Institute of Immunology and National Key Laboratory of Medical Immunology, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, People's Republic of China.
Chen
Guoyou
G
Zheng
Yuanyuan
Y
Lu
Lin
L
Wu
Cong
C
Zhang
Yi
Y
Liu
Qiuyan
Q
Cao
Xuetao
X
D000818:Animals; D002454:Cell Differentiation; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D007093:Imidazoles / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000276:immunology*; D011392:Proline / Q000031:analogs & derivatives / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D017475:Receptors, Nerve Growth Factor / Q000096:biosynthesis*; D015398:Signal Transduction; D013859:Thiocarbamates / Q000494:pharmacology; D051197:Toll-Like Receptor 4 / Q000235:genetics / Q000276:immunology*; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*
D007093:Imidazoles; D008070:Lipopolysaccharides; D016328:NF-kappa B; D011725:Pyridines; D017475:Receptors, Nerve Growth Factor; C517634:Ngfr protein, mouse; D013859:Thiocarbamates; D051197:Toll-Like Receptor 4; C066229:prolinedithiocarbamate; D011392:Proline; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580